Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales

Cytokine

Volumn 52, Issue 3, 2010, Pages 225-229

  Flisiak, Iwona ^a   Zaniewski, Przemysław ^a   Rogalska, Magdalena ^a   MyŚliwiec, Hanna ^a   Jaroszewicz, Jerzy ^a   Chodynicka, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Angiogenesis; PASI; Psoriasis; VEGF

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSORIASIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79953668502     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.09.012     Document Type: Article

References (27)

1. Simonetti O., Lucarini G., Goteri G., Zizzi A., Biagini G., Lo Muzio L., et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006, 19:751-760.
2. Henno A., Blacher S., Lambert C.A., Deroanne C., Noël A., Lapière C., et al. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. J Dermatol Sci 2010, 57:162-169.
3. Chua R.A., Arbiser J.L. The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 2009, 42:574-579.
4. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000, 55:15-35.
5. Bhushan M., McLaughlin B., Weiss J.B., Griffiths C.E. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999, 141:1054-1060.
6. Ren X., Li J., Zhou X., Luo X., Huang N., Wang Y., et al. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology 2009, 219:232-238.
7. Teige I., Hvid H., Svensson L., Kvist P.H., Kemp K. Regulatory T cells control VEGF-dependent skin inflammation. J Invest Dermatol 2009, 129:1437-1445.
8. Man X.Y., Yang X.H., Cai S.Q., Bu Z.Y., Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 2008, 12:649-660.
9. Kiselyov A., Balakin K.V., Tkachenko S.E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Invest Drugs 2007, 16:83-107.
10. Deeva I., Mariani S., De Luca C., Pacifico V., Leoni L., Raskovic D., et al. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine 2010, 49:163-170.
11. Flisiak I., Chodynicka B., Porebski P., Flisiak R. Association between psoriasis severity and transforming growth factor beta 1 and beta 2 in plasma and scales from psoriatic lesions. Cytokine 2002, 19:121-125.
12. Flisiak I., Zaniewski P., Chodynicka B. Plasma TGF-β1, TIMP-1, MMP-1 and IL-18 as combined biomarker of psoriasis activity. Biomarkers 2008, 13:549-556.
13. Kakurai M., Demitsu T., Umemoto N., Kobayashi Y., Inoue-Narita T., Fujita N., et al. Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. Br J Dermatol 2009, 161:1232-1238.
14. Zhou C.L., Yu X.J., Chen L.M., Jiang H., Li C.Y. Corticotropin-releasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes. Regul Pept 2010, 160:115-120.
15. Fredriksson T., Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
16. Creamer D., Allen M., Jaggar R., Stevens R., Bicknell R., Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002, 138:791-796.
17. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1359.
18. Krane J.F., Murphy D.P., Gottlieb A.B., Carter D.M., Hart C.E., Krueger J.G. Increased dermal expression of PDGF receptors in growth activated skin wounds and psoriasis. J Invest Dermatol 1991, 96:983-986.
19. Sepp N.T., Fritsch P., Luger T.A. Endothelial cells and angiogenesis. Exp Dermatol 1997, 6:272-273.
20. Flisiak I., Porebski P., Chodynicka B. Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales. Acta Dermato-venereologica 2006, 86:17-21.
21. Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlström M, Enerbäck C. Elevation of serum EGF and IL-1RA in active psoriasis vulgaris. Br J Dermatol; in press doi:10.1111/j.1365-2133.2010.09990.x. doi:10.1111/j.1365-2133.2010.09990.x.
22. Fink A.M., Cauza E., Hassfeld W., Dunky A., Bayer P.M., Jurecka W., et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007, 25:305-308.
23. Nofal A., Al-Makhzangy I., Attwa E., Nassar A., Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 2009, 23:803-806.
24. Barile S., Medda E., Nisticò L., Bordignon V., Cordiali-Fei P., Carducci M., et al. Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol 2006, 15:368-376.
25. Schonthaler H.B., Huggenberger R., Wculek S.K., Detmar M., Wagner E.F. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009, 106:21264-21269.
26. Bussolati B., Dunk C., Grohman M., Kontos C.D., Mason J., Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001, 159:993-1008.
27. Canavese M., Altruda F., Ruzicka T., Schauber J. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis - a possible target for novel therapies?. J Dermatol Sci 2010, 58:171-176.